Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis
A Phase III, Randomized, Two-armed, Double-blind, Parallel, Active-controlled Clinical Trial to Evaluate Equivalency of the Efficacy and Safety of Ocrelizumab (CinnaGen, Iran) in Comparison to Reference Product, Ocrevus® (Roche, Switzerland) in Patients With Relapsing Multiple Sclerosis
Sponsor: Cinnagen
This PHASE3 trial investigates Multiple Sclerosis and Relapsing-Remitting and is currently completed. Cinnagen leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 1 earlier version
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cinnagen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahvāz, Iran , Hamadan, Iran , Isfahan, Iran , Kerman, Iran , Kermanshah, Iran , Mashhad, Iran , Rasht, Iran , Sari, Iran , Shiraz, Iran , Tabriz, Iran and 1 more location